{
    "Overall_score": {
        "Correlation": 9,
        "Sentiment": 8,
        "Importance": 7,
        "Impact": 6,
        "Duration": 5,
        "Virality": 3,
        "Source_Score": 7,
        "Specificity": 9,
        "Sector_Spread": 6,
        "Tech_Mentions": 2
    },
    "Each_item": [
        {
            "News_content": "BMY 12W triple combo: 89% SVR12 (ITT) in treatment-naive GT-1 patients. Phase III data needed to confirm if efficacy is slightly lower than GILD ABBV",
            "Correlation": 9,
            "Sentiment": 8,
            "Importance": 7,
            "Impact": 6,
            "Duration": 5,
            "Virality": 3,
            "Source_Score": 7,
            "Specificity": 9,
            "Sector_Spread": 6,
            "Tech_Mentions": 2
        }
    ]
}